Alumis Inc. (ALMS)
NASDAQ: ALMS · Real-Time Price · USD
25.18
+0.49 (1.98%)
At close: May 1, 2026, 4:00 PM EDT
25.30
+0.12 (0.48%)
After-hours: May 1, 2026, 6:41 PM EDT
Alumis Revenue
In the year 2025, Alumis had annual revenue of $24.05M. Alumis had revenue of $1.93M in the quarter ending December 31, 2025.
Revenue (ttm)
$24.05M
Revenue Growth
n/a
P/S Ratio
133.18
Revenue / Employee
$107,366
Employees
224
Market Cap
3.20B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 24.05M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionALMS News
- 4 weeks ago - Alumis Transcript: Study update - Transcripts
- 4 weeks ago - Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis - GlobeNewsWire
- 6 weeks ago - Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements - GlobeNewsWire
- 6 weeks ago - Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting - GlobeNewsWire
- 7 weeks ago - Alumis Transcript: Leerink Global Healthcare Conference 2026 - Transcripts
- 2 months ago - Alumis to Present at the Leerink Partners Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Alumis Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference - Transcripts
- 2 months ago - Alumis Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026 - Transcripts